<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04420689</url>
  </required_header>
  <id_info>
    <org_study_id>ALM-488-001</org_study_id>
    <nct_id>NCT04420689</nct_id>
  </id_info>
  <brief_title>A Study of ALM-488 to Highlight Nerves in Patients Undergoing Head &amp; Neck Surgery</brief_title>
  <official_title>Phase 1/2 Trial of ALM-488 in Patients Undergoing Head &amp; Neck Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alume Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alume Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1/2 study of ALM-488 to highlight nerves in patients undergoing head &amp; neck surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of ALM-488 administered as an
      intravenous (IV) infusion to patients undergoing head &amp; neck surgery. The study will also
      characterize the pharmacokinetics of ALM-488 in this subject population and determine the
      dose of ALM-488 needed to generate a fluorescence signal in nerve tissue to enable
      fluorescence recordings and image analysis with an imaging system. The study will also
      evaluate the effect of timing of ALM-488 administration, relative to surgery, on fluorescence
      characteristics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a Phase 1/Phase 2 study in patients undergoing Head &amp; Neck Surgery.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ALM-488 related Adverse Events</measure>
    <time_frame>28 (+5) days</time_frame>
    <description>Incidence of ALM-488 related Adverse Events according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of ALM-488 in blood</measure>
    <time_frame>28 (+5) days</time_frame>
    <description>Concentration of ALM-488 in blood at varying times following ALM-488 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose determination</measure>
    <time_frame>9 months</time_frame>
    <description>To determine the recommended dose of ALM-488.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing determination</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate the effect of timing of administration of ALM-488.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Parotid Neoplasm</condition>
  <condition>Thyroid Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Surgery</condition>
  <condition>Nerve Injury</condition>
  <condition>Imaging</condition>
  <arm_group>
    <arm_group_label>Dose Escalation/De-Escalation Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm of the study will include Dose Escalation/De-Escalation cohorts of ALM-488.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Timing Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm of the study will include Dose Timing cohorts of ALM-488.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALM-488</intervention_name>
    <description>ALM-488 Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.</description>
    <arm_group_label>Dose Escalation/De-Escalation Cohorts</arm_group_label>
    <arm_group_label>Dose Timing Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A neoplasm located in the head and neck.

          2. Primary surgical treatment is by parotidectomy, or thyroidectomy, or cervical neck
             dissection.

          3. Can understand and is willing to sign a written informed consent document.

          4. â‰¥18 years of age.

          5. Life expectancy of at least 6 months.

          6. Normal liver and kidney functions.

          7. If of childbearing potential, must have a negative urine or serum pregnancy test and
             be using a medically acceptable form of contraception (e.g., hormonal birth control,
             intrauterine devices, double-barrier method) or abstinence. The subject, if male, must
             use a medically acceptable form of contraception (e.g. condom) or abstinence.

          8. Plans to undergo head and neck surgery.

        Exclusion Criteria:

          1. Prior radiation or chemotherapy for any prior head and neck neoplasm.

          2. Open surgery in the ipsilateral head and neck within 1 year.

          3. Abnormal cardiac rhythm not controlled with medication, history of stroke, coronary
             events and/or heart failure within 1 year.

          4. Current evidence of renal disease.

          5. Pregnant or breastfeeding.

          6. Unresolved acute toxicity from prior anti-cancer therapy.

          7. History of fluorescein allergy.

          8. Any other criteria deemed by the Principal Investigator that may prevent the patient
             from successfully completing the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dan Harvey, PhD</last_name>
    <phone>858-366-5058</phone>
    <email>clinical.trial@alumebiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harvard-Mass Eye &amp; Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nerve</keyword>
  <keyword>Fluorescence</keyword>
  <keyword>Surgery</keyword>
  <keyword>Imaging</keyword>
  <keyword>Real-time</keyword>
  <keyword>Intraoperative</keyword>
  <keyword>Highlighting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Parotid Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

